Accro Bioscience Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $50M

  • Investors
  • 14

Accro Bioscience General Information

Description

Developer of small-molecule innovative drugs designed for inflammatory, autoimmune diseases, and cancer. The company focuses on the molecular mechanism of regulated cell death and the related pathogenesis in human diseases, thereby improving the current therapeutic standard of targeted disease areas.

Contact Information

Website
www.accropeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit E37, 2nd Floor, North Tower, Building A1
  • Biomedical Industrial Park, Number 218 Xinghu Street
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Unit E37, 2nd Floor, North Tower, Building A1
  • Biomedical Industrial Park, Number 218 Xinghu Street
  • Suzhou, Jiangsu 215000
  • China
+86 0512

Accro Bioscience Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Accro Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 18-May-2026 $50M Completed Generating Revenue
3. Later Stage VC (Series B1) 14-Mar-2025 Completed Generating Revenue
2. Early Stage VC (Series B) 04-Jan-2022 $50M $50M Completed Generating Revenue
1. Early Stage VC (Series A) 02-Feb-2019 Completed Generating Revenue
To view Accro Bioscience’s complete valuation and funding history, request access »

Accro Bioscience Patents

  • 48

    Total Documents Applications and Grants

  • Total Patents Families

  • 25

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Accro Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026170985-A1 Crystal forms of a heterocyclic compound with necroptosis inhibitory activity, preparation methods therefor and uses thereof Pending 14-Feb-2025
WO-2026143206-A1 Compounds as stat6 degrader, composition and application thereof Pending 27-Dec-2024
EP-4831182-A1 Compound having dual degradation activity against irak4 and flt3 proteins, pharmaceutical composition comprising same, and use thereof Pending 20-Dec-2023
WO-2025130871-A1 Compound having dual degradation activity against irak4 and flt3 proteins, pharmaceutical composition comprising same, and use thereof Inactive 20-Dec-2023
EP-4551559-A1 Heteroaryl compounds as inhibitors of tyk2/jak1, composition and application thereof Pending 08-Jul-2022 C07F9/65583
To view Accro Bioscience’s complete patent history, request access »

Accro Bioscience Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cenova Capital Venture Capital Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
OrbiMed Growth/Expansion Minority
TCG Crossover Management Venture Capital Minority
Hefei Innovation Technology Venture Capital Growth/Expansion Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

Accro Bioscience FAQs

  • When was Accro Bioscience founded?

    Accro Bioscience was founded in 2017.

  • Where is Accro Bioscience headquartered?

    Accro Bioscience is headquartered in Suzhou, China.

  • What industry is Accro Bioscience in?

    Accro Bioscience’s primary industry is Drug Discovery.

  • Is Accro Bioscience a private or public company?

    Accro Bioscience is a Private company.

  • What is Accro Bioscience’s current revenue?

    The current revenue for Accro Bioscience is .

  • How much funding has Accro Bioscience raised over time?

    Accro Bioscience has raised $112M.

  • Who are Accro Bioscience’s investors?

    Cenova Capital, LAV (Lilly Asia Fund), OrbiMed, TCG Crossover Management, and Hefei Innovation Technology Venture Capital are 5 of 14 investors who have invested in Accro Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process